Dietmar Rohleder becomes CFO of Haupt Pharma AG
Rohleder takes over as Schwella focuses on production in Berlin
Rohleder takes over responsibility for the areas of finance, accounting and controlling from the previous CFO, Norbert Schwella. As a member of the extended Board committee, Schwella will retain responsibilities for purchasing and IT. In addition, he will be focussing on his role as md of the Group's Berlin production company. Under his leadership, this company has undergone a radical reorganisation over the past two years and today it is Haupt Pharma’s most important site for the production of solid drugs in the OTC segment.
Rohleder has 19 years of working in a wide range of roles in Deutsche Bank's loans and corporate banking business. In 2005 he was appointed to the Board of what is now INVITA AG, where he has been responsible for managing and controlling the holding company ever since.
By appointing Mr Rohleder as the CFO to its holding company Haupt Pharma AG, INVITA AG is demonstrating its support for the strategic path the company is following with the aim of becoming the leading contract manufacturer and developer in Europe.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Manufacturing
Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters
Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Atrogi doses first subjects in human trial of exercise-mimicking oral therapy ATR-258
The Swedish biotech has initiated a human trial of ATR-258, a first-in-class oral β2-adrenergic receptor modulator designed to replicate the metabolic effects of exercise, including fat loss and muscle preservation, without the cardiovascular side effects associated with traditional β2-agonists